DNA Methylation Markers for Breast Cancer Detection in the Developing World.
Publication/Presentation Date
11-1-2019
Abstract
PURPOSE: An unmet need in low-resource countries is an automated breast cancer detection assay to prioritize women who should undergo core breast biopsy and pathologic review. Therefore, we sought to identify and validate a panel of methylated DNA markers to discriminate between cancer and benign breast lesions using cells obtained by fine-needle aspiration (FNA).
RESULTS: In the discovery cohort, 10 of 25 markers were selected that were highly methylated in breast cancer compared with benign tissues by QM-MSP. In the independent test cohort, this panel yielded an AUC of 0.937 (95% CI = 0.900-0.970). In the FNA pilot, we achieved an AUC of 0.960 (95% CI = 0.883-1.0) using the automated cartridge system.
CONCLUSIONS: We developed and piloted a fast and accurate methylation marker-based automated cartridge system to detect breast cancer in FNA samples. This quick ancillary test has the potential to prioritize cancer over benign tissues for expedited pathologic evaluation in poorly resourced countries.
Volume
25
Issue
21
First Page
6357
Last Page
6367
ISSN
1557-3265
Published In/Presented At
Downs, B. M., Mercado-Rodriguez, C., Cimino-Mathews, A., Chen, C., Yuan, J. P., Van Den Berg, E., Cope, L. M., Schmitt, F., Tse, G. M., Ali, S. Z., Meir-Levi, D., Sood, R., Li, J., Richardson, A. L., Mosunjac, M. B., Rizzo, M., Tulac, S., Kocmond, K. J., de Guzman, T., Lai, E. W., … Sukumar, S. (2019). DNA Methylation Markers for Breast Cancer Detection in the Developing World. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(21), 6357–6367. https://doi.org/10.1158/1078-0432.CCR-18-3277
Disciplines
Medicine and Health Sciences
PubMedID
31300453
Department(s)
Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology Residents, Fellows and Residents
Document Type
Article